Is Movantik used for opioid-induced constipation?

What is Movantik and its primary use?

Movantik, also known as naloxegel, is a medication used to treat opioid-induced constipation (OIC) in adults with chronic pain who are receiving and are tolerant to opioid therapy [1]. It is an opioid antagonist that works by blocking opioid receptors in the gut, allowing normal bowel movements to occur.

How does Movantik address opioid-induced constipation?

Opioids can cause constipation by slowing down gut movements and decreasing motility, leading to hardened stools. Movantik's unique mechanism of action, as an opioid antagonist, helps to counteract this effect by blocking the action of opioids on the gut, thus allowing for normal bowel movements.

What are key differences between Movantik and other treatments for OIC?

Movantik is distinct from other treatments, such as linaclotide, lubiprostone, and methylnaltrexone, which also address OIC but through different mechanisms. While Movantik is designed to specifically counteract the opioid-induced effects on the gut, other treatments work by increasing gut motility, hydration, or other mechanisms [2].

What clinical benefits have Movantik shown in treating OIC?

Studies have demonstrated that Movantik is effective in treating OIC in patients with chronic pain, showing improved bowel function and reduced opioid doses [3]. Clinical trials have also shown Movantik to be well-tolerated, with mild side effects.

Additional information

Movantik is available through prescription only and should only be used under the guidance of a healthcare provider. As with any medication, side effects can occur. Patients with a history of opioid use disorder should be carefully monitored when taking Movantik.

Sources:

[1] AstraZeneca: Movantik (naloxegel) [Prescribing Information]. Available at: DrugPatentWatch.com

[2] FDA: Naloxegel (Movantik) for Chronic Pain-Associated Constipation. Available at: FDA.gov

[3] AstraZeneca: TIVUS study – Naloxegel Phase III results for Chronic Pain-Associated Constipation treatment. Presentation at ISPOR 2017 conference.